Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Grid Therapy for Non-Small Cell Lung Cancer Post-Pacific Regimen
NCT05443971Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events. Started Jan 2024; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05443971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443971.